Moxifloxacin Versus Ofloxacin Plus Metronidazole in Uncomplicated Pelvic Inflammatory Disease: Multicenter Randomized Controlled Trials

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01799356

Enrollment

1303

Registered

2013-02-26

Start date

2010-06-30

Completion date

2013-03-31

Last updated

2013-08-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pelvic Inflammatory Disease

Keywords

Treatment, moksifloksasin

Brief summary

We aimed to compare efficacy and safety of combination therapy with oral ofloxacin, 400 mg twice daily, plus oral metronidazole, 500 mg twice daily, for 14 days, with moxifloxacin monotherapy, 400 mg once daily, for 14 days

Interventions

DRUGMoxifloxacin

daily 400 mg moksifloksasin

DRUGOfloxacin

daily 800 mg oflaksasin plus 1000 mg metronidazol treatment

DRUGMetronidazole

daily 1000 mg metronidazol plus 800 mg oflaksasin treatment for uPID

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

SINGLE (Investigator)

Eligibility

Sex/Gender

FEMALE

Age

14 Years to 45 Years

Healthy volunteers

Yes

Inclusion criteria

1. Women diagnosed uncomplicated PID 2. Patients age are between 14 with 45 3. Pelvic tenderness and vaginal discharge

Exclusion criteria

1. Urinary Tract Enfections 2. Tubo-ovarian abscess and complicated PID 3. Hıstory of antibiotics treatment 4. Other pelvic pain causes 5. Endometriosis 6. Delivery,abortion and surgery within last months

Design outcomes

Primary

Measure	Time frame
Clinically cure	21 Days

Secondary

Measure	Time frame
Microbiological cure	21 Days

Countries

Turkey (Türkiye)

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026